chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Muscle weakness, weak shaky joints, confusion, diarrhea, extreme chills, headache, brain fog, numbness, tingling, fatigue
Onset was about 7 days injection and on rising, felt ill, not well, as before only the symptoms were stringer.
Patient endorses headache, nausea, dizziness after receiving vaccination which prompted ER visit one week after vaccination. Followed up in clinic with myself on 5/4/2021 for telephone visit and attributing headache, nausea, constipation to the vaccination. Symptomatic treatment prescribed.
Treatment of COVID-19; Treatment of COVID-19; Dose 1, 2, 3: Moderna; Dose 4, 5, 6: Pfizer / BioNTech; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Sep2022 as dose 5 (booster), single (Lot number: GJ2524), in left arm and on 07Jun2023 as dose 6 (booster), single (Lot number: 6J6743) at the age of 71 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 04Jun2022 as dose 4 (booster), single (Lot number: 045A22A), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 22Jan2021 as dose 1, single (Lot number: 032L20A), in left arm, on 19Feb2021 as dose 2, single (Lot number: 006M29A), in left arm and on 23Oct2021 as dose 3 (booster), single (Lot number: 045C21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "High cholesterol" (unspecified if ongoing). The patient had no known allergies. The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 04Jun2022, outcome "not recovered", described as "Dose 1, 2, 3: Moderna; Dose 4, 5, 6: Pfizer / BioNTech"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Aug2023) Negative, notes: Had negative antigen tests x3; (Aug2023) Negative, notes: Had negative antigen tests x3; (Aug2023) Negative, notes: Had negative antigen tests x3; (31Aug2023) Positive, notes: tested positive on Covid antigen test. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid.
Information has been received from a physician concerning a 13 year old female who on 03-FEB-1998 and 15-MAR-2001 was vaccinated with the first and second dose of MMR II (lot# not reported) respectively. On 23-NOV-2009 the patient was vaccinated with a third dose of MMR II (lot# not reported). On 23-NOV-2009 the patient had the first blood work performed and the results showed IgM was 0.62 and IgG 2.9. On 06-DEC-2009 the patient experienced onset of symptoms and on the same day the patient was diagnosed with mumps. On 06-DEC-2006, the patient also had second blood work performed and the results showed IgM was 0.38, IgG 3.89 and serum amylase 546. The patient was afebrile and had a left side parotitis. At the time of the report, the outcome of mumps was unknown. No further information is available.
Left arm itching, minor swelling of upper arm, started 6-7 hours after the vaccine.
This spontaneous report as received from another health professional refers to a female patient of unknown age. No medical history or concurrent conditions were reported. On 14-FEB-2013 the patient was vaccinated with VARIVAX (merck), 0.5 ml, intramuscular. Lot number was reported as 1700Z with an expiration date of 09-DEC-2012. No other co-suspects were reported. No concomitant medications were reported. It was reported that the patient was administered with an expired dose of VARIVAX (merck) on 14-FEB-2013. No adverse effects were reported. Additional information was not provided. Additional information has been requested.
Paraosmia; Dysgeusia; This is a spontaneous report from a non-contactable physician. A male patient of unknown age received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Apr2021 as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date, the patient experienced parosmia and dysgeusia (metallic taste, sulfur smell). The clinical outcome of the event parosmia and dysgeusia (metallic taste, sulfur smell) were unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Had been feeling like her heart have been skipping a beat; chest pain; This spontaneous case was reported by a consumer and describes the occurrence of EXTRASYSTOLES (Had been feeling like her heart have been skipping a beat) and CHEST PAIN (chest pain) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045J21A and 058F21A) for COVID-19 vaccination.     Concomitant products included MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 23-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EXTRASYSTOLES (Had been feeling like her heart have been skipping a beat) and CHEST PAIN (chest pain). At the time of the report, EXTRASYSTOLES (Had been feeling like her heart have been skipping a beat) and CHEST PAIN (chest pain) outcome was unknown.            No medical history was provided by the reporter. Treatment information was not provided by the reporter.  Company comment: This case concerns a 40-year-old, female patient with no medical history, who experienced the unexpected non serious events of extrasystoles and chest pain. The events occurred approximately 29 day after the second dose of mRNA-1273. As reported, patient had been feeling like her heart have been skipping a beat and also some chest pain. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-436412 (Patient Link).; Sender's Comments: This case concerns a 40-year-old, female patient with no medical history, who experienced the unexpected non serious events of extrasystoles and chest pain. The events occurred approximately 29 day after the second dose of mRNA-1273. As reported, patient had been feeling like her heart have been skipping a beat and also some chest pain. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Increase diffuse pain, highest in my neck, lower back and hips. Increased fatigue (ongoing), periods of extreme fatigue, unable to complete some daily task. Occasional episodes of migraines with dizziness and nausea. An overall feeling of un-wellness.
vomiting; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (vomiting) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VOMITING (vomiting). At the time of the report, VOMITING (vomiting) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: follow up was received on 25-MAY-2021 and contain no significant information
Left arm/shoulder-pain, mild erythema and edema- (Military personel-not much info avalable)
ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY  1/25/2022 - RECURRENCE OF SAME SYMPTOMS
pt recv vax 20FEB96&pt devel a t102.6&pt was lethargic&mottled;tx was cephalosporins&was hospitalized;lab eval upon admission revealed WBC 6800 w/42 segmented neutrophils,33 bands,17 lymphocytes,4monocytes,hgb 8.9;
This spontaneous report as received from a pharmacist refers to a 13 year old patient of unknown gender. No information on patient's medical history or concurrent conditions was provided. On 21-AUG-2015, the patient was inadvertently vaccinated with the dose of M-M-R II (0.5 ml, lot # L008684 expiration date 13-MAR-2017) intramuscularly rather than subcutaneously. The pharmacist was not sure if this M-M-R II dose was the patient's first dose or a booster dose. No adverse effects were reported. Additional information has been requested.
No adverse event; Patient was given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of 0.25mL dosage of the dark blue cap and label with gray border presentation.; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient was given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of 0.25mL dosage of the dark blue cap and label with gray border presentation.) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 215K22A) for COVID-19 prophylaxis.     The patient was not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     In April 2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. In April 2023, the patient experienced WRONG PRODUCT ADMINISTERED (Patient was given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of 0.25mL dosage of the dark blue cap and label with gray border presentation.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient was given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of 0.25mL dosage of the dark blue cap and label with gray border presentation.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient was given at a 0.2mL dosage from the presentation with the dark pink cap with yellow border instead of 0.25mL dosage of the dark blue cap and label with gray border presentation.).    Concomitant medication was not provided.  Doses were administered from 24-Apr-2023 to 28-Apr-2023. Patients were between 6m-5y of age. No reported symptoms. Treatment information was not provided. This case contains information for the 11th of 12th child patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-722123 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-722123:1st patient case (Master case)
Lt deltoid - dark red, warm to touch, firm & woody, tender to palpation, cellulitis, headache. Rt mid-humerus 4 cm area of induration that is blanchable & pruritic/tx with AUGMENTIN and ORAPRED.
No adverse event; The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna; The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 IMMUNISATION (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna), INTERCHANGE OF VACCINE PRODUCTS (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna) and NO ADVERSE EVENT (No adverse event) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    Concurrent medical conditions included Immunocompromised.   On 20-Sep-2021, the patient received third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) .3 milliliter. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Sep-2021, the patient experienced COVID-19 IMMUNISATION (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna) and INTERCHANGE OF VACCINE PRODUCTS (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, COVID-19 IMMUNISATION (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna), INTERCHANGE OF VACCINE PRODUCTS (The third dose was the Pfizer covid vaccine but the patient's two previous covid vaccines were Moderna) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            It was reported that the third dose was the Pfizer COVID vaccine but the patient's two previous COVID vaccines were Moderna.The patient was on daily medication and was on a lot of medicines, not provided the names.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Information has been received from a registered nurse referring to an unspecified number of patients of unknown age and gender. On unspecified dates, the patients were vaccinated with improperly stored doses of (Merck) VARIVAX (lot # K011797, expiration date 21-AUG-2016, dose and route unknown). No adverse effects reported. Additional information has been requested.
Water retention and swelling in legs below knee; Water retention and swelling in legs below knee; Lower Limb Edema; This spontaneous case was reported by a consumer and describes the occurrence of FLUID RETENTION (Water retention and swelling in legs below knee), PERIPHERAL SWELLING (Water retention and swelling in legs below knee) and OEDEMA PERIPHERAL (Lower Limb Edema) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 011J20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension.   On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FLUID RETENTION (Water retention and swelling in legs below knee), PERIPHERAL SWELLING (Water retention and swelling in legs below knee) and OEDEMA PERIPHERAL (Lower Limb Edema). At the time of the report, FLUID RETENTION (Water retention and swelling in legs below knee), PERIPHERAL SWELLING (Water retention and swelling in legs below knee) and OEDEMA PERIPHERAL (Lower Limb Edema) outcome was unknown.            The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.  Relevant concomitant medications included, medications for hypertension were reported.   Treatment information was not provided.    Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Patient's contact details updated, newevent added.
Was given vaccine at a clinic with EMS present.  Approximately 5 minutes after the injection she said she felt lightheaded/dizzy first, some dizziness, with slight tingling of the tongue.  Said her legs felt tingling, hot and hands shook.  She said throat felt slightly tight.  EMS was on sight and they administered her Solumedrol and Benadryl IM.  She was never given an epi injection.  They monitored her HR and O2 Sats.  After she felt symptoms were resolved she did leave the clinic on her own accord.  She returned to her work even though she was advised to go home and rest per medical personal.
Day 5 palpitations and shortness of breath, lessened over 3-4 days. Diagnostic testing only. No treatment.
Pt vaccinated with DTP/OPV experienced prolonged crying greater than 3 hrs after injection.
Pt felt faint--immediately after she had been given the FLUZONE-QUAD shot got up to go to the Dad--then fainted-fell back-hit her head.
Severe pain at injection site.  Severe! I am getting worse as time goes on.  I don?t know what to do. Doctors don?t know anything about it. This is causing me severe anxiety, and pain.
This spontaneous report as received from a Licensed Practical Nurse refers to a patient of 11 years old child patient and unknown gender. On 16-JUL-2014 the patient was vaccinated with a dose of an improperly stored GARDASIL (lot H020901, expiration date 05-JUL-2015) (dose, route, were not reported). No adverse effect was reported. The outcome of events reported was unknown. No product quality complaint was involved. This is one of several reports received from the same source. Additional information has been requested.
Expired Havrix administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 65-year-old female patient who received HAV (Havrix) (batch number 7ya99, expiry date 30th September 2022) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 8th November 2022, the patient received Havrix and Havrix Pre-Filled Syringe Device. On 8th November 2022, unknown after receiving Havrix and Havrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 8-Nov-2022 Reporter's comment: The reporter did not consent to follow-up. Additional supportive information: The patient received an expired dose of Havrix, which led to expired vaccine used. This is report for 2 of 2 linked patients reported by same reporter. Suspect was coded as per narrative information.; Sender's Comments:  US-GSK-US2022163637:Same reporter
Approx. 12 hrs after vaccines given, pt had temp 104 and what sounds like a febrile seizure (eyes rolled back and very stiff).
This case was reported by a healthcare professional, via a sales representative, and described the occurrence of lymph node swelling in a 66-year-old male subject who was vaccinated with BOOSTRIX (GlaxoSmithKline). In February 2012 the subject received a dose of BOOSTRIX (unknown route, unknown arm). In February 2012, less than one month after vaccination with BOOSTRIX, the subject experienced lymph node swelling. The subject sought medical attention at a physician's office. At the time of reporting the event was resolved.
neurological/small tics; covid-19; This unsolicited report was received from the patient's mother via pfizer regarding a 16-year-old male patient. The patient's concurrent conditions and concomitant therapies were not reported. The patient had 4 previous adverse reactions to vaccines.  On an unknown date, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (manufacturer unknown) as prophylaxis (dose, route, lot # and expiration date not reported). Following the vaccine, the patient developed neurological tics (also reported as small tics). On an unspecified date in December 2021, the patient had coronavirus disease (COVID-19) with minor symptoms. Outcome for both events were not reported at the time of this report. The reporter stated that the tics were not related to the vaccine and she believed it was related to an immune disease; whereas causal relationship regarding COVID-19 was not provided.    This is one of several reports received from the same reporter.
CT'S MOTHER REPORTS CT VOMITING 4 HOURS AFTER RECEIVING VACCINE ON 7/31/09 FOLLOWED BY REDNESS, SWELLING, FEVER (UNKNOWN TEMPERATURE)AND LETHARGY. MOTHER REPORTS ALTERNATING TYLENOL AND IBUPROFEN TO CONTROL TEMPERATURE. MOTHER DID NOT SEEK MEDICAL ADVICE BEFORE PRESENTING TO CLINIC ON 8/3/09 WITH 5IN BY 4IN INDURATION AND ERYTHEMATIC AREA ON LEFT THIGH, WARM TO TOUCH. CT ACTIVE AND PLEASANT AND NON-GUARDING OF SITE AT THIS TIME.
Patient is an 83-year-old male with history of hypertension, hyperlipidemia and some sort of abnormal cardiac conduction presenting to the emergency department via EMS from home after a syncopal episode today.  Patient states he was in his living room when he suddenly went down in his living room, he states he was able to somewhat catch himself prior to falling, so he did not hit his head.  He does take a baby aspirin daily.  He denies feeling dizziness, shortness of breath, chest pain or any other symptoms prior to having the syncopal episode.  He states over the past few days he has not felt well, he has had cough and congestion, and decreased appetite.  He denies having nausea or vomiting, however just felt he has not been wanting to eat and has not really drank much for the past few days either.  He did contact his family doctor, who advised him he likely is suffering from a cold/flu.  he denies any injury from this episode today.  Upon arrival to the ED, patient is in atrial fibrillation with RVR, he denies any diagnosis of atrial fibrillation in the past, he states his abnormal cardiac conduction was diagnosed approximately 2 years ago, and he describes it as the impulses going in the wrong direction, however states he was never diagnosed with A-fib.  Upon arrival to the ED, patient denies any pain anywhere. Associated Symptoms: appetite changes, cough, fall, fatigue
1/7/21 fatigue, HA, myalgia, SOA, left ear pain, chills.  Dx'd other viral infection, immune response
Local reaction - edema and erythema, pain (pt. only now recalled having a reaction to Td in past).
3/14/2021 Tightness in chest, attributed to physical work outside, 3/15 still felt tightness, 3/16 getting winded and went to the ER around 5:30pm, they took blood and ran test EKG, X-ray and ECHO complete with TTCV, ultrasound of chest,  and test showed multiple blood clots in both lungs; by this time he was having trouble breathing and was admitted because of the blood clots. He was given Heparin and Vicodin through IV, on 3/17 they ran more test to see where blood clots came from and where they came from but nothing was found in legs. he was in a lot of pain Wednesday and he was sent home on 3/19.
subcutaneous fat/tissue ?necrosis with large (about 4x6 cm) area on left thigh that has no subcutaneous tissue. There seems to be no muscle atrophy or involvement, no pain, just this "divot" in the leg of pretty significant size. It wasn't this large initially, just a dimple in the weeks following the vaccination, but now, almost 6 months later, it is the size described and has stayed that size for a couple of months. No treatment. No symptoms of illness. This was his 4th DTAP and he had no unusual reactions to any before this.